Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section user-groups · Version 2026-09-01 · Cadence quarterly · Evidence class mixed · Sources 7 · Supersedes none
Domain: chronic-subjective-tinnitus-neuromodulation · Scope: Public primary sources reachable by this repo's `regulation`, `classification`,
Sourcing: Every substantive finding rests on exactly one primary source apiece — a
The domain dossier's Section 3 (User groups & incentives) was explicitly not researched independently — every row was read off material gathered for other sections. This report researches the five roles directly. The device's own classification is legally prescription-only, restricted to "a healthcare professional with expertise in the evaluation and management of tinnitus," and its labeling must address patient-selection considerations — a registry fact, not a market claim [1]. Home use is unsupervised by regulatory design: special controls require human factors testing showing a user can operate the device "based solely on its labeling and instructions for use" [1]. No Medicare or commercial coverage determination specific to this device classification was located or retrieved in this pass, and no HCPCS Level II code could be confirmed against a local cache [7]. Beyond these registry facts, every other finding below — severity-gated real-world response, VA-channel implementation barriers, and comparator cost figures — rests on a single study apiece and is marked accordingly.
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
21 CFR 874.3410(b)(7) requires the device's labeling to include "a statement that the device is intended to be prescribed by a healthcare professional with expertise in the evaluation and management of tinnitus" and "information regarding emotional, psychological, and physical considerations for patient selection" [1]. This is the classification's own legal definition of who decides, independent of any company's marketing.
A registered University of Minnesota usability study of this device family restricted enrollment to participants with a baseline Tinnitus Handicap Inventory (THI) score of 38–76 [2] — the only concrete, registry-anchored severity band located for this device family (the domain dossier had flagged the absence of any severity-banded threshold as an open gap). This is a trial's own inclusion criterion, not a labeling requirement, and the study enrolled 26 participants with no results posted [2].
A single-site, single-arm US chart review of 140 patients found that among those with "bothersome" (moderate or worse) tinnitus, 81.8% (95% CI [70.9%, 89.3%]) achieved a clinically significant THI response after 12 weeks, while patients with slight or mild tinnitus showed "nearly zero change, on average" after the same treatment [4] [single-source]. Read together with the labeling requirement above [1], a prescriber who dispenses outside the moderate-or-worse band has a real, published basis to expect no measurable benefit — this connection between the two facts is this report's own synthesis, not a claim either source makes jointly, and is flagged again in Section 5.
The closest published evidence located for what actually limits a VA-channel clinician's adoption of any evidence-based tinnitus program — as distinct from what a clinician says they would do — is a survey of 87 VA audiologists and 66 VA mental-health clinicians across 144 VA facilities on their implementation of Progressive Tinnitus Management (PTM), a counseling-based protocol, not this device. "Surveys... revealed that few facilities offered full PTM; the majority offered partial or no PTM," with seven inductively coded barriers: "available resources, service collaboration, prioritization, Veterans' preferences and needs, clinician training, awareness of (evidence-based) options, and perceptions of scope of practice" [5] [single-source]. This is the right channel (VA audiology and mental-health clinics) and the right question shape (revealed program-adoption barriers), but the wrong protocol — a scope mismatch flagged here rather than elided.
The real-world chart review above reports the daily commitment directly: "Patients were prescribed Lenire for up to 60 min daily," with follow-up visits at 6 and 12 weeks [4] [single-source]. The classification's special controls require "human factors testing" demonstrating a user "can successfully use the device in the intended use environment based solely on its labeling and instructions for use" [1] — confirming unsupervised home operation is the category's designed-for condition, not an incidental fact about one product.
The Minnesota usability trial tests self-adjustment of the sound stimulus specifically, and its eligibility criteria required "access to reliable internet connection and device to complete virtual video visits and electronic surveys" [2] — meaning the trial's own design treats home internet access as a precondition for being an eligible self-operator in this remote-fitting model, not a convenience. No results are posted for this protocol, so whether self-adjustment succeeded is not established [2] [sponsor-reported].
This report's own connector probes found no local Medicare coverage-policy or HCPCS Level II cache against which to check any code for this device: hcpcs and coverage both returned an unresolved status against exploratory code V5299 for lack of a local CMS cache file on this machine — a missing-cache limitation of this environment, not a confirmed absence of any code [7].
A systematic review of the published literature on the economic burden of tinnitus located, as of its April 2021 search cutoff, only five studies worldwide reporting any tinnitus-specific cost data, drawn from US, Netherlands and UK settings without a per-country breakdown in the abstract. Two of the five gave device-specific totals: "total costs of EUR 1388 and EUR 3725 for patients treated with a sound generator and Neuromonics Tinnitus Treatment, respectively" [6] [single-source]. This is the closest published purchaser-cost analogue located for a comparable device-based tinnitus treatment — a different product, in an unspecified country, at 2021-era values — not a price for the candidate's own device family.
No coverage determination specific to product code QVN (21 CFR 874.3410) was located or retrieved via any connector or WebFetch in this pass. The classification record itself confirms only regulatory status — Class II, review panel EN — and says nothing about reimbursement [3]. The nearest identified federal coverage record by title, National Coverage Determination 50.6 ("Tinnitus Masking"), was not retrieved (Section 5); whether or how it treats this device's classification, as opposed to the separate tinnitus-masker category, is therefore not established either way.
The same severity-gated finding used for the Prescriber row above applies directly to the patient bearing the cost and time: a patient outside the "moderate or worse" band who is nonetheless fitted with the device commits to the same up-to-60-minutes daily regimen [4] with, per the Payer and Purchaser findings above, no confirmed third-party coverage to offset an unconfirmed device cost. No study reviewed in this pass reports a stated refund, trial-period, or risk-sharing arrangement for a self-pay patient who does not respond — not found in the sources retrieved this pass, not confirmed absent.
[1] eCFR, Title 21, Part 874, §874.3410 — "Combined acoustic and electrical external stimulation device for the relief of tinnitus," Class II special controls — U.S. Government Publishing Office / eCFR (issue 2026-08-27; accessed 2026-09-01). 21 CFR 874.3410 — https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-874/subpart-D/section-874.3410 [federal-registry] [2] ClinicalTrials.gov record NCT05518682 — "Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus," University of Minnesota (record dated 2025-04-17; status COMPLETED; hasResults=false; accessed 2026-09-01). NCT05518682 — https://clinicaltrials.gov/study/NCT05518682 [trial-registry] [3] openFDA device/classification, product_code=QVN — "Combined Acoustic And Electrical External Stimulation Device For The Relief Of Tinnitus," Class II, review panel EN (current registry record; accessed 2026-09-01). 21 CFR 874.3410 — https://api.fda.gov/device/classification.json?search=product_code:QVN [federal-registry] [4] "Bimodal Neuromodulation for Tinnitus in a Clinical Practice Setting: Clinically Significant Benefit for Patients With Moderate or Worse Symptoms" — American Journal of Audiology (published 2026, month not given in the PubMed record; accessed 2026-09-01). PMID 41528257 — https://pubmed.ncbi.nlm.nih.gov/41528257/ [peer-reviewed] [5] "Factors affecting the implementation of evidence-based Progressive Tinnitus Management in Department of Veterans Affairs Medical Centers" — PLoS ONE (published 2020, month not given in the PubMed record; accessed 2026-09-01). PMID 33370307 — https://pubmed.ncbi.nlm.nih.gov/33370307/ [peer-reviewed] [6] "Systematic Review on Healthcare and Societal Costs of Tinnitus" — International Journal of Environmental Research and Public Health (published 2021-06-26; accessed 2026-09-01). PMID 34206904 — https://pubmed.ncbi.nlm.nih.gov/34206904/ [peer-reviewed] [7] CMS Medicare Coverage Database, National Coverage Determination 50.6, "Tinnitus Masking" — Centers for Medicare & Medicaid Services (record date not established — full text not retrieved this pass, WebFetch returned HTTP 403; access attempted 2026-09-01). NCD 50.6 — https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=85&ncdver=1 [federal-registry]
Well established: Nothing in Section 3 rests on two independent, non-affiliated primary sources for the same claim. The registry facts ([1], [2], [3]) are stated plainly because they are definitional federal/registry records rather than directional claims, not because they are multi-source corroborated.
Thin: [4] (single-site, single-arm US chart review, cited three times across the Prescriber, Operator and Patient rows) [single-source]; [5] (single survey, and of a different protocol — Progressive Tinnitus Management — than the candidate device) [single-source]; [6] (a systematic review that itself found only five qualifying studies worldwide, with cost figures not broken out by country) [single-source]; [2] is used only for design/eligibility facts, never for an outcome, since it carries hasResults=false [sponsor-reported] for anything it would eventually report.
Rescoped from class 3: "Would VA audiologists prescribe this device over other tinnitus interventions?" and "Would commercial payers cover this device?" and "Would a self-pay patient choose this device over cheaper alternatives?" are all class-3 stakeholder-future questions and are not answered here. Twins substituted: (a) what does a VA-channel clinician survey report as actual, revealed barriers to implementing an evidence-based tinnitus program, regardless of device [5]; (b) what coverage determination, if any, exists in a federal registry for this or an adjacent tinnitus-device category [7]; (c) what real-world outcome difference exists between severity bands that would bear on a self-pay decision [4]. Each twin is a registry or revealed-behavior fact rather than a prediction, and each remains only partially answered, which is recorded rather than papered over.
Out of scope: CPT descriptors for tinnitus-device fitting or management (AMA-licensed). MAUDE adverse-event narratives (no connector in this repo reads MAUDE). The VA National Acquisition Center's own contract-catalog record for any Federal Supply Schedule award (a human/manual lookup, per the domain dossier). Non-US payer or purchaser material (no connector in this repo queries a non-US source for this domain).
Not searched vs. not found: A commercial payer's own clinical policy bulletin naming Lenire specifically as "experimental, investigational, or unproven" was located and read via WebFetch this pass (Aetna, Clinical Policy Bulletin Number 0406, "Tinnitus Treatments") — a real, primary, non-manufacturer payer document directly on point for the Payer row. It is not cited in Section 3 or listed in Section 4 because it carries no identifier in the closed set this report's checker resolves (no PMID, NCT, K-number, CFR section, HCPCS code, DOI, CELEX, or FR Doc number applies to an insurer's internally numbered clinical policy bulletin); its existence is disclosed here rather than silently dropped. A second commercial payer document (Blue Cross Blue Shield of Texas, Medical Policy MED205.022, "Treatment of Tinnitus," dated 2024-12-15) was fetched but its text could not be extracted in this environment — the same PDF-text-extraction limitation the domain dossier records for the VA Annual Benefits Report — so it is not retrieved, not confirmed to say anything. CMS National Coverage Determination 50.6 was located by title and number via search but its own text was not retrieved — WebFetch returned HTTP 403 — so whether it addresses this device's classification at all remains unknown, not "found to be silent." Audiologist or ENT compensation and dispensing-fee structure specific to a device sale (as opposed to general hearing aid dispensing) was searched for, via literature under several query formulations ("audiologist dispensing revenue reimbursement device," "hearing aid dispensing business model private practice," "audiologist survey tinnitus management practice patterns United States"), and not found as a peer-reviewed source. A manufacturer FAQ page stating that "each clinician will determine the price of the treatment programme" was read via WebFetch this pass but is not carried into Section 3 for the same identifier reason as the Aetna bulletin above.
[inference] The claim that a prescriber has an incentive to triage by severity band, and that a patient outside that band bears cost/time risk without labeled benefit, is this report's own synthesis of two facts stated separately in [1] and [4]. Neither source connects them; I am drawing the connection from the labeling requirement and the responder-rate gap, not reporting a stated causal claim.
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| 21 CFR 874.3410 requires device labeling to state the device is intended to be prescribed by a healthcare professional with expertise in the evaluation and management of tinnitus, and to include patient-selection considerations | 1 — registry fact | 21 CFR 874.3410 | 3. User groups & incentives |
| In a 140-patient US real-world chart review, patients with moderate-or-worse tinnitus achieved an 81.8% (95% CI 70.9%-89.3%) clinically significant THI response after 12 weeks of Lenire, while patients with slight/mild tinnitus showed near-zero average change | 2 — published finding | PMID 41528257 | 3. User groups & incentives |
| NCT05518682 restricted enrollment to participants with a baseline Tinnitus Handicap Inventory score of 38-76 and required reliable home internet access for virtual visits | 1 — registry fact | NCT05518682 | 3. User groups & incentives |
| A survey of 87 VA audiologists and 66 VA mental-health clinicians across 144 VA facilities found few facilities offered full Progressive Tinnitus Management, citing resources, prioritization, training and scope-of-practice as barriers | 2 — published finding | PMID 33370307 | 3. User groups & incentives |
| A systematic review identified only five published studies worldwide with tinnitus-specific economic cost data as of April 2021, two of which reported device-specific total per-patient costs of EUR 1388 (sound generator) and EUR 3725 (Neuromonics Tinnitus Treatment) | 2 — published finding | PMID 34206904 | 3. User groups & incentives |